BI partners with Tsinghua for immuno therapies
Boehringer Ingelheim (BI) and Tsinghua University in Beijing have announced a collaboration aiming to research and develop immunological therapies for infectious diseases. Scientists will work in the BI-Tsinghua University Joint Research Centre for Immuno-Infection to harness the mechanisms of immune modulation to combat infectious diseases. The collaboration brings together the leading expertise of Tsinghua University in infectious disease research and immunology with Boehringer Ingelheim’s experience in the development of novel therapies for patients suffering from diseases with high unmet medical need and its comprehensive research and development programs in cancer immunology and immune modulation. This collaboration is an initiative of Boehringer Ingelheim’s Research Beyond Borders
(RBB) and Cancer Immunology and Immune Modulation Research Departments. Immuno-infection is a new focus area for BI’s RBB department, which also focuses on gene therapy, regenerative medicine and the role of the microbiome in human health and disease. With the new collaboration, BI further expands its activities in the growing biomedical innovation hot spot of China. By combining a focus on cutting-edge science with a long-term view, the company aspires to develop the next generation of medical breakthroughs to improve the lives of patients suffering from diseases with high unmet medical needs.